ClinicalTrials.gg
TerminatedNCT05618613ELONAUpdated Jul 21, 2026Results posted

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

A Phase 1/2 interventional study of Elacestrant and Onapristone in Breast Cancer, sponsored by Context Therapeutics Inc.. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.

Sponsored by Context Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

How we know · 6 judgments

Why this study was terminated
Sponsor decision to discontinue onapristone development.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, Phase 1b-2 study of elacestrant in combination with onapristone in patients with advanced/metastatic ER+/PgR+/HER2- breast cancer.

Read the detailed description

This is a multicenter, phase 1b-2 trial. The phase 1b part of the trial is open label and aims to determine the recommended Phase 2 dose (RP2D) of onapristone and elacestrant when administered together. The Phase 2 part of the trial will evaluate the efficacy and safety of this combination in patients with ER+/PgR+/HER2- advanced/metastatic breast cancer after prior therapy with a CDK4/6 inhibitor.

02

Conditions studied

  • Breast Cancer

Browse trials for

03

In context

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

This study's enrollment of 4 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Context Therapeutics Inc. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women or men aged ≥18 years, at the time of signature. Note: Pre- and peri-menopausal women must receive goserelin for at least one month prior to initiating trial therapy, during the trial, and for at least one month after end of trial therapy. Men must receive triptorelin for at least one month prior to initiating trial therapy, during the trial and for at least one month after end of trial therapy.
  2. Histopathologically or confirmed ER+, PgR+, -, breast cancer, per local laboratory, as per the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines (Allison et al, 2020). Note: In the context of this trial, ER and PgR status will be considered positive if ≥10% of tumor cells demonstrate positive nuclear staining by immunohistochemistry.
  3. At least one as per version 1.1. Note: Patients with stable brain or subdural are allowed if the patient has completed local therapy and has discontinued the use of for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) or symptoms of must be stable for at least 4 weeks before starting study treatment.
  4. Prior therapy with an aromatase inhibitor or fulvestrant + a CDK4/6 inhibitor in the metastatic setting or in the setting if within 12 months of last dose of adjuvant therapy. Note: Prior therapy with everolimus is allowed.
  5. performance status of 0 or 1.
  6. Patient has adequate bone marrow and organ function, as defined by the following laboratory values:

    1. (ANC) ≥1.5 × 109/L,
    2. ≥100 × 109/L,
    3. ≥9.0 g/dL,
    4. Potassium, sodium, calcium (corrected for serum albumin), and magnesium grade ≤1,
    5. -based creatinine clearance ≥50 mL/min. Note: Creatinine clearance (male) = ([140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72) Creatinine clearance (female) = (0.85 × [140-age in years] × weight in kg)/ ([serum creatinine in mg/dL] × 72),
    6. Serum albumin ≥3.0 g/dL (≥30 g/L),
    7. In absence of liver metastases, (ALT) and aspartate aminotransferase (AST) ≤3.0 × . If the patient has liver metastases, ALT and AST ≤5 × ULN,
    8. Total serum \<1.5 × ULN except for patients with Gilbert's syndrome who may be included if the total serum bilirubin is ≤3.0 × ULN or direct bilirubin ≤1.5 × ULN.

Exclusion criteria

Exclusion Criteria:

  1. Active or newly diagnosed , including meningeal carcinomatosis.
  2. Breast cancer treatment-naïve patients in the setting.
  3. Prior therapy with elacestrant, onapristone, or chemotherapy in the metastatic setting.
  4. Patient has a concurrent or history of invasive malignancy within 3 years of enrollment, with the exception of basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix that has completed curative therapy.
  5. Uncontrolled significant active infections.

    1. Patients with virus (HBV) and/or virus (HCV) infection must have undetectable viral load during screening.
    2. Patients known to be + are allowed as long as they have undetectable viral load at baseline.
  6. Major surgery within 4 weeks before starting trial therapy.
  7. Inability to take oral medication, or history of malabsorption syndrome or any other uncontrolled gastrointestinal condition.
  8. Females of who:

    1. Within 28 days before study entry, did not use a highly effective method of .
    2. Do not agree to use a highly effective method of contraception throughout the entire study period and for 28 days after trial therapy discontinuation.
  9. Males who do not agree to abstain from donating sperm, or to use a highly effective method of contraception, during the course of the treatment period and for 28 days thereafter.
  10. Known intolerance to either study drug or any of the .
  11. Patient is currently receiving or received any of the following medications prior to first dose of trial therapy:

    1. Known strong or moderate inducers or inhibitors of cytochrome P450 (CYP) 3A4 within 14 days or 5 half-lives, whichever is shorter, (Refer to http://medicine.iupui.edu/clinpharm/ddis/),
    2. Herbal preparations/medications within 7 days. These include, but are not limited to, St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng.
    3. anti-cancer therapy with 21 days or 5 half-lives, whichever is shorter.
    4. Vaccination, including but not limited to vaccination against COVID-19, during the 7 days prior to randomization.
  12. Evidence of ongoing alcohol or drug abuse.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Elacestrant / Onapristone

    Elacestrant and Onapristone combination

    Drug: Elacestrant · Drug: Onapristone

Interventions

  • Elacestrant 200mg, 300mg, or 400mg once daily oral dosing in cycles of 28 days.

    Also known as: RAD1901

  • Onapristone 40mg or 50mg twice daily oral dosing in cycles of 28 days.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs) During First Cycle

    DLTs were pre-specified toxicities occurring during Cycle 1 (28 days) and considered at least possibly related to study treatment, based on CTCAE criteria. Assessment of safety and tolerability to determine the recommended Phase 2 dose (RP2D). DLT defined as dose associated with \<33% of patients experiencing DLT (≤1 patient out of 6 DLT-evaluable patients).

    Time frame: First 28 days (Cycle 1)

  2. Objective Response Rate (ORR)

    ORR was defined as the proportion of patients achieving confirmed complete or partial response per RECIST v1.1; Phase 2 was not initiated, and no patients were enrolled.

    Time frame: Assessed every 8 weeks until disease progression, up to approximately 6 months

Secondary outcomes

  1. Adverse Events (AEs)

    Adverse events were collected from first dose through last safety assessment and graded using NCI CTCAE v5.0. Incidence and severity of AEs was collected.

    Time frame: From first dose until 30 days after last dose (up to 183 days)

  2. Serious Adverse Events (SAEs)

    Serious Adverse events were collected from first dose through last safety assessment and graded using NCI CTCAE v5.0. Incidence and severity of SAEs was collected

    Time frame: 183 days

  3. Evaluate the Maximum Plasma Concentration (Cmax) of Elacestrant as Well as Onapristone and Their Metabolites (Phase 1)

    AUC₀-ₜₐᵤ, Cₘₐₓ, Tₘₐₓ, and Cₜᵣₒᵤ for elacestrant, onapristone, and metabolites. PK samples were obtained from 2 patients at Cycle 1, Day 15 at the following timepoints: predose (hour 0), 1, 2, 3, 6, 8, 12, and 24 hours post-dose. Data was collected as represented below for 2 patients

    Time frame: 15 Days

  4. Evaluate the Time of the Maximum Observed Plasma Concentration (Tmax) of Elacestrant as Well as Onapristone and Their Metabolites (Phase 1).

    AUC₀-ₜₐᵤ, Cₘₐₓ, Tₘₐₓ, and Cₜᵣₒᵤ for elacestrant, onapristone, and metabolites. PK samples were obtained from 2 patients at Cycle 1, Day 15 at the following timepoints: predose (hour 0), 1, 2, 3, 6, 8, 12, and 24 hours post-dose. Data was collected as represented below for 2 patients

    Time frame: 15 Days

  5. Evaluate Duration of Response

    Time from first CR/PR until progression or death

    Time frame: From first documented CR/PR until progression or death, up to 183 days

  6. Evaluate Clinical Benefit Rate

    Proportion of subjects achieving a best overall or complete response, or durable stable disease (duration is at least 23 weeks)

    Time frame: 183 days

  7. Evaluate Progression-free Survival

    Time from the date of the first dose to the date of the first documentation of disease progression or death, whichever occurs first.

    Time frame: 183 Days

07

Results

Posted Jul 21, 2026
Limitations and caveats
The study was terminated early after four patients were treated in Phase 1b Cohort 1.

Participant flow

Five patients were screened and four were enrolled into Phase 1b Cohort 1 at three U.S. sites.

Participant flow — Overall Study
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started4000
Completed0000
Not completed4000
Withdrew: Lack of efficacy4000

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs) During First Cycle

DLTs were pre-specified toxicities occurring during Cycle 1 (28 days) and considered at least possibly related to study treatment, based on CTCAE criteria. Assessment of safety and tolerability to determine the recommended Phase 2 dose (RP2D). DLT defined as dose associated with \<33% of patients experiencing DLT (≤1 patient out of 6 DLT-evaluable patients).

Time frame:
First 28 days (Cycle 1)
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLTs) During First Cycle
ParticipantsElacestrant / Onapristone
Number of Participants With Dose-Limiting Toxicities (DLTs) During First Cycle1
SecondaryAdverse Events (AEs)

Adverse events were collected from first dose through last safety assessment and graded using NCI CTCAE v5.0. Incidence and severity of AEs was collected.

Time frame:
From first dose until 30 days after last dose (up to 183 days)
Reported as:
Count of participants · Participants
Adverse Events (AEs)
ParticipantsElacestrant / Onapristone
Adverse Events (AEs)3
SecondarySerious Adverse Events (SAEs)

Serious Adverse events were collected from first dose through last safety assessment and graded using NCI CTCAE v5.0. Incidence and severity of SAEs was collected

Time frame:
183 days
Reported as:
Count of participants · Participants
Serious Adverse Events (SAEs)
ParticipantsElacestrant / Onapristone
Serious Adverse Events (SAEs)0
SecondaryEvaluate the Maximum Plasma Concentration (Cmax) of Elacestrant as Well as Onapristone and Their Metabolites (Phase 1)

AUC₀-ₜₐᵤ, Cₘₐₓ, Tₘₐₓ, and Cₜᵣₒᵤ for elacestrant, onapristone, and metabolites. PK samples were obtained from 2 patients at Cycle 1, Day 15 at the following timepoints: predose (hour 0), 1, 2, 3, 6, 8, 12, and 24 hours post-dose. Data was collected as represented below for 2 patients

Time frame:
15 Days
Reported as:
Number · ng/mL
Evaluate the Maximum Plasma Concentration (Cmax) of Elacestrant as Well as Onapristone and Their Metabolites (Phase 1)
ng/mLOnapristone PharmacokineticsDesmethyl Onapristone (Metabolite) Pharmacokinetics
Patient 12,25070.2
Patient 21,26042.0
SecondaryEvaluate the Time of the Maximum Observed Plasma Concentration (Tmax) of Elacestrant as Well as Onapristone and Their Metabolites (Phase 1).

AUC₀-ₜₐᵤ, Cₘₐₓ, Tₘₐₓ, and Cₜᵣₒᵤ for elacestrant, onapristone, and metabolites. PK samples were obtained from 2 patients at Cycle 1, Day 15 at the following timepoints: predose (hour 0), 1, 2, 3, 6, 8, 12, and 24 hours post-dose. Data was collected as represented below for 2 patients

Time frame:
15 Days
Reported as:
Number · hours
Evaluate the Time of the Maximum Observed Plasma Concentration (Tmax) of Elacestrant as Well as Onapristone and Their Metabolites (Phase 1).
hoursOnapristone Pharmacokinetics Tmax
Patient 16
Patient 26
SecondaryEvaluate Duration of Response

Time from first CR/PR until progression or death

Time frame:
From first documented CR/PR until progression or death, up to 183 days
Reported as:
Count of participants · Participants
Evaluate Duration of Response
ParticipantsElacestrant / Onapristone
Evaluate Duration of Response0
PrimaryObjective Response Rate (ORR)

ORR was defined as the proportion of patients achieving confirmed complete or partial response per RECIST v1.1; Phase 2 was not initiated, and no patients were enrolled.

Time frame:
Assessed every 8 weeks until disease progression, up to approximately 6 months
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsElacestrant / Onapristone
Objective Response Rate (ORR)0
SecondaryEvaluate Clinical Benefit Rate

Proportion of subjects achieving a best overall or complete response, or durable stable disease (duration is at least 23 weeks)

Time frame:
183 days
Reported as:
Count of participants · Participants
Evaluate Clinical Benefit Rate
ParticipantsResponse Category
Stable Disease (SD)1
Progressive Disease3
SecondaryEvaluate Progression-free Survival

Time from the date of the first dose to the date of the first documentation of disease progression or death, whichever occurs first.

Time frame:
183 Days
Reported as:
Median · Days
Evaluate Progression-free Survival
DaysElacestrant / Onapristone
Evaluate Progression-free Survival85 (55 to 115)

Adverse events

Collected over From first dose until 30 days after last dose (up to 183 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 10/4 (0%)0/4 (0%)3/4 (75%)
Most frequent other events
Most frequent other events
EventCohort 1
FatigueGeneral disorders1/4
Urinary tract infectionInfections and infestations1/4
Blood cholesterol increasedInvestigations1/4
Muscle spasmsMusculoskeletal and connective tissue disorders1/4
InsomniaPsychiatric disorders1/4
Rash maculo-papularSkin and subcutaneous tissue disorders1/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1
<=18 years4
Between 18 and 65 years0
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1
Female4
Male0
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Cohort 1
Breast Cancer Subtype
Breast Cancer Subtype(Participants)Cohort 1
Count of participants4
Disease Status
Disease Status(Participants)Cohort 1
Count of participants4
ECOG Performance Status
ECOG Performance Status(Participants)Cohort 1
Count of participants4
08

Study locations

3 sites
  • Cancer Treatment Centers of America - Western Regional Medical Center
    Phoenix, Arizona 85338, United States
  • Cancer Treatment Centers of America - Midwestern Regional Center
    Zion, Illinois 60099, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Jun 2023, 6 months.

Results were first posted in Jul 2026, 3 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Nov 16, 2022
StartActual
Dec 2, 2022
Primary completionActual
Jun 23, 2023
CompletionActual
Jun 23, 2023
Results first posted
Jul 21, 2026
Last update
Jul 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05618613
Lead sponsor
Context Therapeutics Inc.
Responsible party
Sponsor
First posted
Nov 16, 2022
Start date
Dec 2, 2022
Primary completion
Jun 23, 2023
Completion
Jun 23, 2023
Results posted
Jul 21, 2026
Last update
Jul 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Onapristone

Start the discussion